56
Views
15
CrossRef citations to date
0
Altmetric
Correspondence

Specificity of anti‐sp100 antibody for primary biliary cirrhosis

, , , &
Pages 405-406 | Published online: 08 Jul 2009

References

  • Szostecki C, Guldner HH, Will H. Autoantibodies against ‘nuclear dots’ in primary biliary cirrhosis. Semin Liver Dis 1997;17:71–8.
  • Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003;7:759–77.
  • Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431–7.
  • Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003;98:241–3.
  • Wichmann I, Montes-Cano MA, Respaldiza N, Alvarez A, Walter K, Franco E, et al. Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies. Scand J Gastroenterol 2003;38:996–9.
  • Muratori P, Muratori L, Cassani F, Terlizzi P, Lenzi M, Rodrigo L, et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 2002;127:172–5.
  • Bogdanos DP, Pares A, Rodes J, Vergani D. Primary biliary cirrhosis specific anti-nuclear antibodies in patients from Spain. Am J Gastroenterol 2004. In press.
  • Invernizzi P, Battezzati PM, Crosignani A, Perego F, Poli F, Morabito A, et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol 2003;38:401–6.

References

  • Szostecki C, Guldner HH, Will H. Autoantibodies against ‘nuclear dots’ in primary biliary cirrhosis. Semin Liver Dis 1997;17:71–8.
  • Wichmann I, Montes-Cano MA, Respaldiza N, Alvarez A, Walter K, Franco E, et al. Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies. Scand J Gastroenterol 2003;38:996–9.
  • Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003;98:241–3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.